High OCT4 Expression Might Be Associated with an Aggressive Phenotype in Rectal Cancer.

Lina Lambis-Anaya, Mashiel Fernández-Ruiz, Yamil Liscano, Amileth Suarez-Causado
Author Information
  1. Lina Lambis-Anaya: Grupo Prometeus & Biomedicina Aplicada a las Ciencias Clínicas, Facultad de Medicina, Universidad de Cartagena, Cartagena 130014, Colombia. ORCID
  2. Mashiel Fernández-Ruiz: Grupo Prometeus & Biomedicina Aplicada a las Ciencias Clínicas, Facultad de Medicina, Universidad de Cartagena, Cartagena 130014, Colombia. ORCID
  3. Yamil Liscano: Grupo de Investigación en Salud Integral (GISI), Departamento Facultad de Salud, Universidad Santiago de Cali, Cali 760035, Colombia. ORCID
  4. Amileth Suarez-Causado: Grupo Prometeus & Biomedicina Aplicada a las Ciencias Clínicas, Facultad de Medicina, Universidad de Cartagena, Cartagena 130014, Colombia.

Abstract

Rectal cancer (RC) is one of the most common malignant neoplasms, and cancer stem cells (CSCs) of the intestinal tract have been implicated in its origin. The oncofetal protein OCT4 has been linked to neoplastic processes, but its role and clinical significance in RC are unknown. This study investigates the expression of the stem cell marker OCT4 related to clinical-pathological characteristics and its clinical significance in RC patients. The expression level of stem cell marker OCT4 was analyzed in 22 primary rectal tumors by western blot. The association between OCT4 protein expression and the clinical-pathological features of tumors was evaluated by χ test and Fisher's exact test. We demonstrated that the expression of the stem cell marker OCT4 was observed in tumor tissue but not adjacent non-tumor tissue. High expression of the stem cell marker OCT4 was significantly associated with histological differentiation grade ( = 0.039), tumor invasion level ( = 0.004), lymph node involvement ( = 0.044), tumor-node-metastasis (TNM) stage ( = 0.002), and clinical stage ( = 0.021). These findings suggest that high OCT4 expression is associated with a more aggressive RC phenotype, with a greater likelihood of progression and metastasis. These results shed light on the importance of targeting this CSC marker to attenuate RC progression.

Keywords

References

  1. Int J Mol Sci. 2023 Mar 09;24(6): [PMID: 36982333]
  2. J Physiol Biochem. 2023 May;79(2):261-272 [PMID: 36495464]
  3. J Gastrointest Cancer. 2019 Dec;50(4):824-837 [PMID: 30136202]
  4. Curr Mol Med. 2019;19(1):54-75 [PMID: 30854966]
  5. Colomb Med (Cali). 2018 Mar 30;49(1):55-62 [PMID: 29983464]
  6. Indian J Pathol Microbiol. 2022 Apr-Jun;65(2):328-335 [PMID: 35435367]
  7. J Exp Clin Cancer Res. 2019 Nov 26;38(1):474 [PMID: 31771617]
  8. Front Oncol. 2022 Aug 10;12:876257 [PMID: 36033461]
  9. Ann Surg Oncol. 2009 Dec;16(12):3488-98 [PMID: 19657699]
  10. Am J Cancer Res. 2020 Jun 01;10(6):1888-1899 [PMID: 32642298]
  11. Cancers (Basel). 2019 Sep 08;11(9): [PMID: 31500347]
  12. Cancer Rep (Hoboken). 2023 Apr;6(4):e1766 [PMID: 36538945]
  13. Biosci Rep. 2019 May 10;39(5): [PMID: 30979828]
  14. Int J Environ Res Public Health. 2021 Aug 03;18(15): [PMID: 34360522]
  15. Cancer Cell Int. 2021 Feb 27;21(1):139 [PMID: 33639931]
  16. Int J Cancer. 2019 Jul 15;145(2):318-326 [PMID: 30303536]
  17. J Gastrointest Oncol. 2022 Dec;13(6):2989-3008 [PMID: 36636075]
  18. Ther Adv Urol. 2019 Sep 29;11:1756287219875576 [PMID: 31632462]
  19. Essays Biochem. 2022 Sep 16;66(4):423-433 [PMID: 35670043]
  20. Mol Cell Oncol. 2020 Jul 14;7(5):1788366 [PMID: 32944642]
  21. Front Oncol. 2022 Sep 16;12:953790 [PMID: 36185248]
  22. J Gastrointest Cancer. 2020 Mar;51(1):41-47 [PMID: 30628031]
  23. Cancers (Basel). 2021 Jan 12;13(2): [PMID: 33445692]
  24. Oncogene. 2019 Aug;38(34):6226-6239 [PMID: 31308488]
  25. Stem Cells Int. 2019 May 02;2019:7896524 [PMID: 31191684]
  26. Gene. 2022 Jun 15;827:146448 [PMID: 35337852]
  27. Cell. 2010 Jan 8;140(1):62-73 [PMID: 20074520]
  28. Biomed Res Int. 2018 Jul 12;2018:3424956 [PMID: 30112378]
  29. Hematol Oncol Clin North Am. 2022 Jun;36(3):521-537 [PMID: 35577705]
  30. Front Cell Dev Biol. 2020 Jun 18;8:442 [PMID: 32626705]
  31. Int J Stem Cells. 2020 Nov 30;13(3):312-325 [PMID: 32840233]
  32. Cancer Res. 2021 May 15;81(10):2730-2744 [PMID: 33741693]
  33. Cancer Biol Ther. 2023 Dec 31;24(1):2195363 [PMID: 37005380]
  34. Int J Mol Sci. 2018 Aug 30;19(9): [PMID: 30200215]
  35. Mol Biol Rep. 2020 Sep;47(9):6793-6805 [PMID: 32865703]
  36. Mol Biotechnol. 2022 May;64(5):560-574 [PMID: 35022996]
  37. CA Cancer J Clin. 2023 May-Jun;73(3):233-254 [PMID: 36856579]
  38. Pathog Dis. 2022 Aug 17;80(1): [PMID: 35776950]
  39. Yonsei Med J. 2018 Jan;59(1):35-42 [PMID: 29214774]
  40. Mol Oncol. 2019 Feb;13(2):109-131 [PMID: 30520562]
  41. Funct Integr Genomics. 2022 Dec;22(6):1345-1360 [PMID: 35987846]
  42. Cell Prolif. 2019 Jul;52(4):e12612 [PMID: 31012189]
  43. Ann Clin Lab Sci. 2020 Mar;50(2):266-269 [PMID: 32366567]

Grants

  1. 807 national grant for science, technology and innovation in health projects 2018 (project code 110780763299 contract 804-2018)/Colciencias
  2. Convocatoria Interna No. 02-2023/Universidad Santiago de Cali

Word Cloud

Created with Highcharts 10.0.0OCT4stemexpressioncancerRCmarker=0cellproteinclinicalRectalcellsoncofetalsignificanceclinical-pathologicallevelrectaltumorstesttumortissueHighassociatedstageprogressiononecommonmalignantneoplasmsCSCsintestinaltractimplicatedoriginlinkedneoplasticprocessesroleunknownstudyinvestigatesrelatedcharacteristicspatientsanalyzed22primarywesternblotassociationfeaturesevaluatedχFisher'sexactdemonstratedobservedadjacentnon-tumorsignificantlyhistologicaldifferentiationgrade039invasion004lymphnodeinvolvement044tumor-node-metastasisTNM002021findingssuggesthighaggressivephenotypegreaterlikelihoodmetastasisresultsshedlightimportancetargetingCSCattenuateExpressionMightAssociatedAggressivePhenotypeCancercolorectal

Similar Articles

Cited By